Shari Rogal

Dr. Shari Rogal

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in Implementation Science
Verified
Journal Article
Open access
PDF file
EWEva N. Woodward
Eva N. Woodward
MMMonica M. Matthieu
Monica M. Matthieu
UUUchenna S. Uchendu
Uchenna S. Uchendu
SRShari Rogal
Shari Rogal
JKJoAnn E. Kirchner
JoAnn E. Kirchner
Researchers could benefit from methodological advancements to advance uptake of new treatments while also reducing healthcare disparities. A comprehensive determinants framework for healthcare disparity implementation challenges is essential to accurately understand an implementation problem and select implementation strategies. We integrated and modified two conceptual frameworks—one from implementation science and one from healthcare disparities research to develop the Health Equity Implementation Framework. We applied the Health Equity Implementation Framework to a historical healthcare disparity challenge—hepatitis C virus (HCV) and its treatment among Black patients seeking care in the US Department of Veterans Affairs (VA). A specific implementation assessment at the patient level was needed to understand any barriers to increasing uptake of HCV treatment, independent of cost. We conducted a preliminary study to assess how feasible it was for researchers to use the Health Equity Implementation Framework. We applied the framework to design the qualitative interview guide and interpret results. Using quantitative data to screen potential participants, this preliminary study consisted of semi-structured interviews with a purposively selected sample of Black, rural-dwelling, older adult VA patients (N = 12), living with HCV, from VA medical clinics in the Southern part of the USA. The Health Equity Implementation Framework was feasible for implementation researchers. Barriers and facilitators were identified at all levels including the patient, provider (recipients), patient-provider interaction (clinical encounter), characteristics of treatment (innovation), and healthcare system (inner and outer context). Some barriers reflected general implementation issues (e.g., poor care coordination after testing positive for HCV). Other barriers were related to healthcare disparities and likely unique to racial minority patients (e.g., testimonials from Black peers about racial discrimination at VA). We identified several facilitators, including patient enthusiasm to obtain treatment because of its high cure rates, and VA clinics that offset HCV stigma by protecting patient confidentiality. The Health Equity Implementation Framework showcases one way to modify an implementation framework to better assess health equity determinants as well. Researchers may be able to optimize the scientific yield of research inquiries by identifying and addressing factors that promote or impede implementation of novel treatments in addition to eliminating healthcare disparities.

22 April 2022 in Hepatology
Verified
Journal Article
Closed access
SRShari Rogal
Shari Rogal
LHLissi Hansen
Lissi Hansen
APArpan Patel
Arpan Patel
NUNneka N. Ufere
Nneka N. Ufere
MVManisha Verma
Manisha Verma
FKFasiha Kanwal
Fasiha Kanwal

22 May 2020 in Hepatology
Verified
Journal Article
Closed access
SRShari Rogal
Shari Rogal
AYAda Youk
Ada Youk
HZHongwei Zhang
Hongwei Zhang
WGWalid F. Gellad
Walid F. Gellad
MFMichael J. Fine
Michael J. Fine
KKKevin L. Kraemer
Kevin L. Kraemer

3 March 2020 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
MDMichael A. Dunn
Michael A. Dunn
SRShari Rogal
Shari Rogal
ADAndres Duarte‐Rojo
Andres Duarte‐Rojo
JLJennifer C. Lai
Jennifer C. Lai

20 February 2013 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SRShari Rogal
Shari Rogal
MDM. A. Dew
M. A. Dew
PFP. Fontes
P. Fontes
ADA. F. DiMartini
A. F. DiMartini
While depression after liver transplantation (LTX) is associated with decreased survival, the effects of treating depression remain unknown. We assessed a previously described, prospective cohort of 167 patients transplanted for alcohol-related liver disease from 1998 to 2003. Depressive symptoms were measured with the Beck Depression Inventory serially throughout the first posttransplant year. Adequacy of antidepressant treatment was measured with the Antidepressant Treatment History Form. Using Cox-proportional Hazards modeling, survival times were assessed for recipients with no depression versus depression with adequate medications versus depression with inadequate medications. Seventy-two recipients had depressive symptoms in the first posttransplant year. Of these, 43% (n = 31) received adequate pharmacotherapy and 57% (n = 41) received inadequate (n = 7) or no pharmacotherapy (n = 34). After a median follow-up time of 9.5 years, 32% of the inadequately treated depressed group survived versus 52% of the adequately treated group and 56% of the nondepressed group (p = 0.006). Compared to the nondepressed group, those with adequately treated depression had no significant difference in survival. However, recipients with depression and inadequate pharmacotherapy had decreased survival times compared to nondepressed recipients (HR for death = 2.44, 95% CI = 1.45, 4.11), controlling for other known confounders. The factor most strongly linked to long-term mortality after liver transplantation in this cohort was untreated depression.

11 May 2017 in Implementation Science
Verified
Journal Article
Open access
PDF file
SRShari Rogal
Shari Rogal
VYVera Yakovchenko
Vera Yakovchenko
TWThomas Waltz
Thomas Waltz
BPByron J. Powell
Byron J. Powell
JKJoAnn E. Kirchner
JoAnn E. Kirchner
MCMatthew J. Chinman
Matthew J. Chinman
Hepatitis C virus (HCV) is a common and highly morbid illness. New medications that have much higher cure rates have become the new evidence-based practice in the field. Understanding the implementation of these new medications nationally provides an opportunity to advance the understanding of the role of implementation strategies in clinical outcomes on a large scale. The Expert Recommendations for Implementing Change (ERIC) study defined discrete implementation strategies and clustered these strategies into groups. The present evaluation assessed the use of these strategies and clusters in the context of HCV treatment across the US Department of Veterans Affairs (VA), Veterans Health Administration, the largest provider of HCV care nationally. A 73-item survey was developed and sent to all VA sites treating HCV via electronic survey, to assess whether or not a site used each ERIC-defined implementation strategy related to employing the new HCV medication in 2014. VA national data regarding the number of Veterans starting on the new HCV medications at each site were collected. The associations between treatment starts and number and type of implementation strategies were assessed. A total of 80 (62%) sites responded. Respondents endorsed an average of 25 ± 14 strategies. The number of treatment starts was positively correlated with the total number of strategies endorsed (r = 0.43, p < 0.001). Quartile of treatment starts was significantly associated with the number of strategies endorsed (p < 0.01), with the top quartile endorsing a median of 33 strategies, compared to 15 strategies in the lowest quartile. There were significant differences in the types of strategies endorsed by sites in the highest and lowest quartiles of treatment starts. Four of the 10 top strategies for sites in the top quartile had significant correlations with treatment starts compared to only 1 of the 10 top strategies in the bottom quartile sites. Overall, only 3 of the top 15 most frequently used strategies were associated with treatment. These results suggest that sites that used a greater number of implementation strategies were able to deliver more evidence-based treatment in HCV. The current assessment also demonstrates the feasibility of electronic self-reporting to evaluate ERIC strategies on a large scale. These results provide initial evidence for the clinical relevance of the ERIC strategies in a real-world implementation setting on a large scale. This is an initial step in identifying which strategies are associated with the uptake of evidence-based practices in nationwide healthcare systems.